Open access
Jul 2026
Discovery of XNW5004 as a novel EZH2 inhibitor that enhances anti-tumor immunity and synergizes with PD-1 blockade immunotherapy in lung adenocarcinoma
The EZH2 inhibitor XNW5004 enhances anti-tumor immunity and synergistically interacts with PD-1 blockade immunotherapy in LUAD, establishing this combinatorial approach as a promising therapeutic strategy.
Zhihuan Lin, Wenjuan Ma, Hai-Shuang Sun et al.
· Journal of Translational Med... · 0 citations